TCL Archive Working Group Proposes “Equitable” Schema For Determining Cancer Center Core Grants July 3, 2013
TCL Archive In Brief: BRI Gets New FCRF Basic Research Contract; Senate Subcommittee Less Generous Than House October 2, 1987
TCL Archive Von Eschenbach takes leave of absence from NCI, resigns from C-Change board. Acting FDA commissioner’s drug approval strategy rooted in unproven science. Von Eschenbach told NCI deputies he might drop in on meetings. Who’s really in charge? October 7, 2005
